Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks. RESEARCH DESIGN AND METHODS: Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients. The primary end point was change in hemoglobin A1c (HbA1c). Outcomes are reported adhering to consensus recommendations on reporting of AP trials. RESULTS: Twenty-nine patients completed the trial. HbA1c, 7.0 ± 0.8% at the start of AP use, improved to 6.7 ± 0.6% after 12 weeks (−0.3, 95% CI −0.5 to −0.2, P < 0.001). Compared with the SAP run-in, CGM time spent in the hypoglycemic range improved during the day from 5.0 to 1.9% (−3.1, 95% CI −4.1 to −2.1, P < 0.001) and overnight from 4.1 to 1.1% (−3.1, 95% CI −4.2 to −1.9, P < 0.001). Whereas carbohydrate ratios were adapted to a larger extent initially with minimal changes thereafter, basal insulin was adapted throughout. Approximately 10% of adaptation recommendations were manually overridden. There were no protocol-related serious adverse events. CONCLUSIONS: Use of our novel adaptive AP yielded significant reductions in HbA1c and hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 1×
“1% in larger studies of outpatient AP, and the automation involved has increased (3,11,12,15,26).”
BackgroundSelf-citationHome Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Outcome measures for artificial pancreas clinical trials: a consensus report
Maahs, D. M., Buckingham, B. A., Castle, J. R., Cinar, A., Damiano, E. R., Dassau, E., DeVries, J. H., Doyle, F. J., Griffen, S. C., Haidar, A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2716 · Cited by 211 · cited 1×
“based outcome measures are reported consistent with the recent AP outcomes measures consensus statement (24).”
ResultSelf-citationKovatchev, B., Cheng, P., Anderson, S. M., Pinsker, J. E., Boscari, F., Buckingham, B. A., Doyle, F. J., Hood, K. K., Brown, S. A., Breton, M. D., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0333 · Cited by 141
Self-citationHsu, W. C., Lau, K. H. K., Huang, R., Ghiloni, S., Le, H., Gilroy, S., Abrahamson, M., & Moore, J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0160 · Cited by 135
Multinational Home Use of Closed-Loop Control Is Safe and Effective
Anderson, S. M., Raghinaru, D., Pinsker, J. E., Boscari, F., Renard, E., Buckingham, B. A., Nimri, R., Doyle, F. J., Brown, S. A., Keith-Hynes, P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2468 · Cited by 120
Self-citationThe Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes
Kovatchev, B., Tamborlane, W. V., Cefalu, W. T., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc16-0824 · Cited by 95
Self-citation
Cited by
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
The year of transition from research to clinical practice
Kovatchev, B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.170 · Cited by 48
Self-citationHughes, J., Gautier, T., Colmegna, P., Fabris, C., & Breton, M. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820973193 · Cited by 34
Self-citationPinsker, J. E., Dassau, E., Deshpande, S., Raghinaru, D., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Church, M. M., Desrochers, H., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0084 · Cited by 18
Self-citationSchiavon, M., Galderisi, A., Basu, A., Kudva, Y. C., Cengiz, E., & Dalla Man, C. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0397 · Cited by 8
“15,16 However, the S ISP method was originally developed and validated on data collected in strictly controlled experimental conditions, that is, with well-spaced consecutive meals (meal-to-meal interval of at least 6 h) and no occurrence of hypoglycemic events, 11 and thus its performances are…”
Self-citationArtificial intelligence in diabetes management
Thomas, A., Gopi, V. P., & Francis, B. (2024) · Advances in Artificial Intelligence · doi:10.1016/b978-0-443-19073-5.00002-1 · Cited by 3
Metadata
- Authors
- Dassau, E., Pinsker, J. E., Kudva, Y. C., Brown, S. A., Gondhalekar, R., Dalla Man, C., Patek, S., Schiavon, M., Dadlani, V., Dasanayake, I., Church, M. M., Carter, R. E., Bevier, W. C., Huyett, L. M., Hughes, J., Anderson, S., Lv, D., Schertz, E., Emory, E., McCrady-Spitzer, S. K., Jean, T., Bradley, P. K., Hinshaw, L., Laguna Sanz, A. J., Basu, A., Kovatchev, B., Cobelli, C., & Doyle, F. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-10-13
- Volume
- 40
- Issue
- 12
- Pages
- 1719-1726
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2763814022
- Cited by
- 85
- References
- 10
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.